This focused issue on “Multimodal management of locally advanced N2 non-small cell lung cancer” is edited by Dr. Mariano Provencio.
Oncology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain
Professor Mariano Provencio graduated in Medicine and Surgery in 1986 from the University Alcalá de Madrid, and gained his doctorate cum laude from the same university in 1997.
He specialised as a resident physician in Medical Oncology in the Hospital Universitario Puerta de Hierro, in Madrid. His background was completed in 1995 when he was awarded the European Certificate in Medical Oncology in Paris. He later spent time at the Memorial Sloan-Kettering Cancer Center, New York in 2003, at MD Anderson, Houston in 2006 and 2012, and at the Lee Moffit Cancer Center, Tampa, in 2009. After finishing his residency, he joined the Medical Oncology Service in Puerta de Hierro Hospital in Madrid.
In 2011 he was appointed Head of the Medical Oncology Department in Puerta de Hierro University Hospital Majadahonda, Madrid, and became the Director of the Puerta de Hierro Research Institute. He is a Full Professor in the Autonomous University of Madrid.
He has authored or co-authored approximately 280 peer-reviewed papers, as well as several book chapters. Since 2014, Professor Provencio has been President of the Spanish Lung Cancer Group.
He serves in the European Society of Medical Oncology (ESMO) as a member of the Publishing Working Group.
Focused issue outline:
- Epidemiology of Lung Cancer stage III
- Prognostic factors in stage III non-small cell lung cancer
- Mediastinal staging for non-small cell lung cancer
- Induction treatment in stage IIIA/N2 non-small cell lung cancer
- Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant/ALK translocation Non-Small-Cell Lung Cancer
- Emerging biomarkers for immunotherapy in early non-small cell lung cancer
- SBRT combined with concurrent chemoradiation in stage III
- Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer
- Salvage surgery after definitive chemo-radiotherapy for patients with Non-Small Cell Lung Cancer
- Minimal invasive surgery in locally advanced N2 non-small cell lung cancer